Business Context and Reporting Period
Company: TECHNE Corporation (BIO-TECHNE Corp)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 1997
Overview: TECHNE is a holding company with two wholly-owned subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) in Minneapolis, MN, and R&D Systems Europe Ltd. in Abingdon, England. The company operates two primary divisions: Hematology (controls and calibrators for blood analysis instruments) and Biotechnology (cytokines, antibodies, and assay kits for research and clinical diagnostics). In fiscal 1997, the company restructured R&D Europe to focus on distribution, withdrawing from the molecular biology market and transferring manufacturing activities to the US.
Key Financial Metrics
| Metric | Fiscal 1997 | Fiscal 1996 | Fiscal 1995 |
|---|---|---|---|
| Net Sales | $60,923,750 | $54,589,054 | $47,716,166 |
| Gross Margin | $41,828,923 (68.7%) | $35,590,123 (65.2%) | $29,252,569 (61.3%) |
| Net Earnings | $10,881,662 | $8,637,870 | $6,706,042 |
| Earnings Per Share | $1.12 | $0.89 | $0.70 |
| Operating Cash Flow | $12,476,548 | $9,759,549 | $7,313,658 |
| Cash & Short-term Investments | $24,752,257 | $19,249,535 | $15,945,223 |
| Long-term Debt | $0 | $0 | $0 |
| Working Capital | $34,899,000 | $28,260,000 | $23,687,000 |
Revenue Mix (Fiscal 1997): Biotechnology Division (52%), R&D Europe (31%), Hematology Division (17%).
Expenses: R&D expenses were $11.7 million (19.2% of sales). Selling, General, and Administrative (SG&A) expenses were $14.6 million (23.9% of sales).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 12% ($6.3 million) compared to fiscal 1996. Approximately 74% of this increase was driven by higher sales of proteins and antibodies in the Biotechnology Division.
- Margin Expansion: Gross margin percentage improved from 65.2% to 68.7%. This was driven by lower royalty expenses (conclusion of Amgen royalties), favorable exchange rates for R&D Europe, and increased production volumes.
- Hematology Decline: Hematology product sales decreased by $683,481 due to the loss of a significant OEM customer at the end of fiscal 1996, partially offset by higher retail sales.
- Restructuring Charge: SG&A expenses included a one-time restructuring charge of approximately $450,000 related to R&D Europe's withdrawal from the molecular biology market.
- Stock Repurchases: The company repurchased and retired 127,300 shares of common stock for $3.2 million in fiscal 1997, compared to 36,200 shares for $676,000 in fiscal 1996.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Management expects to meet future cash requirements through existing funds and operating cash flow.
- Capital expenditures for fiscal 1998 are projected at approximately $3 million, including $1 million for building remodeling.
- The company plans to continue developing new cytokines, antibodies, and assay kits for the research market.
Subsequent Event:
- Post-fiscal year-end, the company signed a letter of intent to invest up to $5 million over two years in a start-up company developing therapeutics based on chemokine biology, for approximately 40% ownership.
Risks and Contingencies:
- Competition & Obsolescence: The biotechnology industry faces rapid technological change. Competitors with greater resources may develop superior products or obtain regulatory approvals faster.
- Patents: The company has not conducted a comprehensive patent infringement study. There is a risk of unintentional infringement or failure to secure necessary patents.
- Regulatory: Hematology controls and clinical diagnostic kits are subject to FDA regulation. Delays in approvals could adversely affect revenue.
- Key Personnel: Success depends on retaining qualified scientific and production personnel.
Investor Verification Checklist
- OEM Customer Concentration: Verify the impact of the lost OEM customer on the Hematology Division and the stability of remaining OEM contracts (which accounted for 46% of Hematology revenue).
- R&D Europe Restructuring: Assess the long-term financial impact of the restructuring charge and the shift of manufacturing activities from Europe to the US.
- Patent Portfolio: Review the status of patent applications and licensing agreements, given the company's admission of not conducting a full infringement study.
- Subsequent Investment: Monitor the progress of the $5 million investment in the chemokine start-up company and the associated performance milestones.
- Stock Repurchase Program: Confirm the status of the remaining $5 million authorization for stock repurchases announced in April 1997.